Vimseltinib – CSF1R inhibitor
Chronic graft-versus-host disease (cGVHD)
About This Program
Deciphera is currently enrolling patients in a Phase 2 study of vimseltinib in adults with active chronic Graft-Versus-Host Disease (cGVHD). To learn more about this study, click here.